At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
Olaratumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b Study of Olaratumab, Doxorubicin and Ifosfamide in the Treatment of Patients With Advanced or Metastatic Soft Tissue Sarcoma
In Brief
A Phase 1 clinical trial evaluating Olaratumab, Doxorubicin, and 2 other interventions for Soft Tissue Sarcoma. Completed, enrolled 24 participants across 6 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate the safety of ifosfamide when added to the combination regimen of olaratumab and doxorubicin in participants with advanced or metastatic soft tissue sarcoma (STS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSoft Tissue Sarcoma
CountriesGermany, Italy, United States
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartOct 2017
Primary CompletionApr 2019
Study CompletionAug 2019
TodayJul 2026
First PostedSep 14, 2017
Enrollment StartOct 18, 2017
Primary CompletionApr 29, 2019
Study CompletionAug 25, 2019
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.8 years ago
Interventions
Olaratumabdrug
Administered IV
Doxorubicindrug
Administered IV
Ifosfamidedrug
Administered IV
Mesnadrug
Administered per standard of care